PODD - Earnings call transcript Q4 2024

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation Fourth Quarter and Full Year 2024 Earnings Call. [Operator Instructions] As a reminder, this conference call is being recorded.

I would now like to turn the conference over to your host, June Lazaroff, Senior Director, Investor Relations. Please go ahead.

June Lazaroff

you Year us XXXX thank Quarter Insulet's and Full and Earnings afternoon, for for joining Fourth Good Call. and Chadwick, With President me Financial Maria and Hollingshead, Officer Chief Chief Executive today Officer; and are Treasurer. Jim Ana

presentation. Both our the the discussing XXXX as fourth website. our section guidance results on call supplemental are and website year the as Also press of Investor full Relations release quarter well of replay this earnings and our is available our on our

we and begin, certain expectations. made differ of we a cautionary that Before remind call explanation for statements filings the current detailed during limitations you such this statements of of statements. may from SEC inherent in Please to the could course refer be our forward-looking materially the

the measures assessing non-GAAP to effect cash supplemental and they non-GAAP and tax performance, revenue free align We our others constant which management are EBITDA, discuss to the growth helpful operating as currency excluding we will adjusted effective from our also uses with exchange, respect period, revenue, believe for flow. period is that measures rate foreign performance well. financial of These measures with including in

regarding dollar currency basis. on unless stated, financial the on year-over-year constant percentage growth be a all Additionally, year-over-year rates, changes will revenue otherwise be reported of and commentary a exception with basis which will

will I Jim. the call that, turn to With over

James Hollingshead

growth We for as strong us. well across you Thank of business fourth milestones thank objectives. several concluded incredible one you, achieving the year every margin June. afternoon, Good a our quarter, joining an with very and and as

X, the international type and robust continue expand U.S. see type demand X in Omnipod now to available both in to X rapidly continue and to patients markets. and momentum We for

constant marked for ninth XX% in billion over generated year first $X our more the revenue history. in or revenue consecutive and currency growth, time we of XXXX Insulet's

years, X revenue full first just XXXX. top line. our $X in billion In we we achieved have in context, year doubled For

starts also the year-over-year year-over-year We the both both quarter. grow customer the fourth second sequentially and plan markets. for international new start international in of and half our on in in year growth resulted delivered U.S. to new customer U.S. and This

new the grew X X starts type and also type in populations We both U.S. customer in

recurring am I and we and And proud X have estimated are to active of share Omnipod given creation us customer to XXX,XXX our which using and pleased is elevates global supported Omnipod. high milestone an to continuing by value users. for a team revenue customers customers growth. million that Reaching have new that these, XXX,XXX entire future is a achieved model our X.X retention growth tremendous stronger global position is And customer

positioned we Our longer-term X horizon. of have as ongoing achievements XXXX proof the adoption and widespread with overwhelming and momentum Omnipod out look enter strong and are acceptance of us over the

We our objectives growing great and in international U.S. our confidence strategic and plans have our executing across markets. to continue

made across financial will But progress X focus the to platform Omnipod our to commitment our will strategy in for our and Ana through work internationally. our growth what by both to through of innovation our our ongoing X type means drive access you type outlook. initiatives data; of to Omnipod cascade this first, lead fueled in X first, and second, X U.S.; X third, advance terms strategic areas: I highlight the our and take

a Omnipod from continue establish X these broad forward. Starting to be compatibilities and develop to which with position our our The driver our includes allowed smartphones cascade with our of us will to and market-leading and has platform sensors. and strengthen innovation, looking expand work compatibility with

was heard from one X with of Omnipod GX, that In key iOS in and the U.S. the Omnipod new in app October, have iOS factors integrated the we X. we users choosing launched many

Our iOS and makes changing, iOS, has Custom which have simpler. for to timesavers Since Foods app remained including Feedback our and normalcy. switched X offers in over that feature, life Omnipod unique their of phrases iPhone. mealtime freedom on this remain like Podders, are extremely capabilities first with And of iOS enhanced positive, we using users launch XX% the half to U.S. track GX year. including launching

have In integrated November, X X FreeStyle the we are sensor Omnipod launched Plus in Libre Abbott's proud with U.S. to

GX in We continue X Omnipod ramp also retail to Dexcom's with pharmacy.

given Omnipod quarter, launched our U.S. customers the launched mid-XXXX markets in U.S. of customers over of Omnipod end international the XX% are in over XXXX. were XX% international and that achievements and In fourth X X as of fully in the we only These significant of using X. had

revenue are our same more Omnipod X in in or the proud connected technology them than X that automated combined. customer-centric market. and to us prior is where is terrific X Omnipod system which essentially meet no tubeless are helped insulin have It saw In delivery the innovation, has they on technology. We delivered customers to period. AID coincidence most on XXXX, the our doubled that bring we launches on years integrations

value-added We materials together. user also for integrated their The to this we patients be forward patients engagement optimize to as our identify to coming the Omnipod and or a personalized market roll platform devices service data, for utilization and is trends learning and announce Discover am workstation next limited Discover excited connecting updates Omnipod management, insights forward digital U.S. health in release of dynamics and from over data will Discover, out patient's months leap these the a clinicians Omnipod with patient a clinician's track platform accessible experience outcomes. quarters. across HCPs and sharing discuss usage to I diabetes insulin Today, management smartphone. look and new and a and

be of people. diabetes to last week, was indication of type SECURE-TXD will leveraged use In the These with published. support and our lives X for trials, manuscript adults findings clinical our Omnipod transform in X millions

the RADIANT Diabetes our for at study shared Advanced Additionally, be Treatments & in Technologies results conference next month. Amsterdam will from

studies And STRIVE commence continues also enrollment [ to ] next will algorithm, EVOLUTION to later commitment year. in with test research advance SmartAdjust this will further the further our of we closed world-class phase validate technology are with trials month. our our algorithm our Our clinical fully study, which platforms, to investment These evidence loop which enhancements continue commencing our next through evidence.

for the to Turning growth leading strategic U.S. focus X. our X type second and ongoing area, in type

offered quarter, the This from consistent the technology the to continue incredibly on the long market the we with new tremendous MDI. people customer and fourth with X testament people living previously and diabetes. is X. for were to on have a In over We XX% of into U.S. prior type our value excited type are simplicity to best starts expanding quarters, bring

leadership Since to we been market for build have our we type market. working X in clearance X received label FDA for type relentlessly diabetes August, the in expansion X position Omnipod

As X diabetes very a opportunity for millions It's the and important for to who a AID type with for reminder, we are market the need of us indication. first X type insulin. living in patients

are This the ramped that using new expanded addressable XX% X market users this includes quarter, market live commercially available population. than intensive type significantly X MDI. million X.X X.X of customer majority has for Omnipod. who U.S., and who diabetes. total insulin We with Insulet is fourth current market X% In people requiring with insulin pump people our in less over as our U.S. making of adoption X penetrated over type Omnipod type the the by this starts million to we on patient estimate indication the represented X For users

other long awareness. portion market runway and a our The is leveraging approximately of commercialization are includes the basal-only use X penetrated. market This barely to a every opportunity, day, and tremendous, proven reach playbook insulin million people drive of that and on creates therapy we that

U.S. and To sales are to reach, force expand we more engage our patients prescribers. our growing

last this discussed and involves expansion sales adding organization. quarter, more the is we wholesale to street feet a on our change not As

XX% XXXX. reach insulin-intensive to our the this X.X We direct increase million of to expansion the X sales in expect population type over of

filled the have quarter. and expect trained of date, be To sales X/X expanded majority the our roles first we to by over of end of those we roles, the

work an sequentially in X of with Omnipod and HCPs Our prescribing We quarter. U.S. type patients for engaging at fourth increase to number of saw over team type increase prescribing the hard the XX% therapy. X is HCPs in

in and great we sales X. type we As on individuals we quarter, Omnipod the saw those invested customers success new our with diabetes, from DTC quickly and efforts having in fourth marketing in X are increase to an getting leads also

type and and fourth We we by efforts are the in progress and X in proud both remain we type made the U.S. the quarter, committed to commercial advancing motivated X

area focus expansion. strategic third Turning to our international of

Our great international making is business also progress.

we're a testament U.K. France to in the is and reach patients more goes. everywhere and in continue seeing adoption strong the We it Germany, X. This the early Omnipod Netherlands. and It of wins power to

this Omnipod international And to January, Sweden. X We over in of available Norway we are year. launches. launch accelerating Finland, became X new X Italy, course countries European with countries: Libre X in Plus GX In commercially and and the Denmark, additional plan

with expand in quarter to more on rollout diabetes. more to year, options also with international through U.K. this planned first for sensor of Omnipod with the with and GX and are our We people Netherlands starting integration, sensor markets track follow our the providing X launches

we had our terrific are a proof continuing we lead. that closing, to In achievements our build and year, on are

relentlessly XXXX, forward advance with the we diabetes Omnipod remain through focused we X. will industry driving As on

competitors the last MDI brought our including have to all patients than from XXXX. over more several combined AID We of years, technology in

off investments Omnipod time to of for nearly number growing Our writing HCPs XX,XXX. the and with paid X scripts have

experience and competitive over We distinct decades X have moats. of

safety proven factor well patch form replicate. us product to took Our a scale IP. pump and with unique quality, very is high difficult and It build yield, has years protected to at very

access or pay-as-you-go in the are a Our Part customers $X to many our of of D or less. And essentially deliver our through us economics less customers of Medicare a co-pay only the reimbursement, has majority pharmacy space have allowed form pump diabetes The now $XX U.S. a $X given widespread is we month, copay. affordable channel. paid with with the which day insulin factor

and customer data we release cloud, be for to improve to will emerging continue market and algorithms us. connected customer of limited outcomes. to our data the to Discover, with Omnipod experience X to an are And use Every able improve optimize the Omnipod is moat

category deep we a see which to we strengthen, ourselves moats, these Given as of one. continue

best field their getting customers, As supporting selves our and we for their work amazing years Malaysia all with I for and clearance our the service clinical X of work acknowledge team, of site global of improve every for that an operations and supported of schedule day customer XXX,XXX new to running our to our to type from our up bringing team ahead and teams mission Insulet, incredible lives and celebrate FDA XX to you want Insulet our our year. team Thank all living people diabetes. for serving

than We excited are ever the more path about ahead.

Day announcing Investor in on Massachusetts mind, that that will at today, With X. an our host Acton, we we are June headquarters

We in join of months, weeks upcoming can will hope the further us. and we many you provide details and

walk With to through Ana that, will I guidance. results turn the our and over to call you

Ana Chadwick

and you, Thank afternoon, Jim, everyone. good

operationally. are We year financially, and very conclude to strong pleased a clinically

Looking to year. for optimistic another XXXX, ahead we exciting are

revenue of year represented Gross comprised margin the ninth currency for billion, of impressive prior XX% Omnipod was XX% Insulet. margin and The of XX.X%, XXXX, and International revenue and consecutive $X.X operating year which an of full marked revenue currency more XX% we growth XX.X%. year growth was XX%. growth constant U.S. growth Omnipod or was of of the of constant delivered over For growth

estimated utilization versus the For our and stable year. global trends year, prior full remained retention

results geography and every strength Omnipod tremendous of of executed on culminating of we Our the getting vision of demonstrate team, more global our in the serve, customers. our dedication recent our milestone who patients platform ongoing active XXX,XXX in

and we customer for over In plan and revenue We new customer both to starts achieved in our new our dollars. total U.S. the revenue the of quarter year. second prior our grow growth in starts year, fourth XX% of year-over-year on resulting highest international total delivered quarter, half sequentially growth and

X new markets also type starts U.S. and sequentially the and We grew year-over-year both customer in in type X

high XX.X%, Let provide by Omnipod U.S. X. details strong ongoing for of on grew fourth results. demand driven end above the revenue more guidance me our the quarter range, Omnipod just now

primarily continue total rate which As million quarter included XXXX basis a impacted an fourth dynamics, fourth reminder, by the X,XXX stocking of points. we to our driven expanding million and base. as volume $XX by of revenue approximately was estimated increasing X our U.S. XXXX quarter growth $XX growth customer

continued we innovations, which extending support platform our customer As Jim of are cascade will discussed, Omnipod X growth. the through

experienced FDA X clearance the throughout new starts in continued in after we customer that August fourth Additionally, ramp type quarter. the the

X meaningfully type contribute long-term opportunity presents expansion it XXXX. to for We in growth given expect significant business a our model. the label to revenue our And annuity-based

international to markets. Turning

quarter, another adoption reported approximately by exceptional a was at the currency of Growth and Our point a basis, team was foreign of prior XX.X% achieving our points growth, delivered On unfavorable our X. guide. was revenue the year, high guidance. demand continued which strong tailwind over Omnipod driven versus XX basis end basis was XX which

with the recent seeing increasingly also Omnipod feedback and to planned, will launches in the and Omnipod X play continue in strong in our X drive and Netherlands, momentum role and pivotal France along recent Omnipod from we're Italy our with Germany. We're of Plus U.K. market future across We early Libre With X launches in adoption growth an positive pleased the growth strategy. our Nordics integrations. X international the

Turning and to Revenue XX.X% Drug in was partner. due above to increase an guidance range orders Delivery. our from our grew

revenue our and manufacturing Fourth the U.S. basis pricing expansion. deliver fourth year, primarily for are channel, gross quarter margin gross through strong quarter, In improved was XX.X%, by pleased driven the growth margin XXX prior X pharmacy markets addition efficiencies. to we up exceptional over Omnipod in international volume points to

across drive continue global and expansion scale drive as operational margin we We excellence our execute initiatives business. to to our

innovation. launches was we business XX.X%, support our XX.X%. to invested in R&D increased grew near-term We gearing trajectory, growth dollars continue with pipeline in as fund to and line including our of for strong EBITDA our adjusted once Operating expectations we globally. expenses as again up margin margin Operating our was

results. year, prior pleased While last to of year we due with stocking benefits are this the very dynamics down margin from the strong

tax allowance, tax been the in for has we non-GAAP perspective, approximately out adjusted a in quarter, benefit, valuation a resulting $XX million noncash From fourth released of our which purposes.

full non-GAAP the the quarter fourth Our tax year rate effective was and XX%. for XX%, was

to cash million facility. the $XXX cash Turning with the under equivalents and credit and year We our available full million over cash and liquidity. ended $XXX in

that for for investing year represents to cash commitment profile $XXX delivering on profitable the Our we cash growth. flow and free in premium milestone our the generating a and was financial million, a business long-term as execution continue

outlook. Now turning to our XXXX

revenue revenue year, growth XX% growth full the For to XX%. to XX% we XX% expect company and total total of Omnipod of

is As our a reminder, a revenue growth guidance on constant currency basis.

strong we continue Omnipod, by of XX%, X growth revenue model we and For X. U.S. our expect XX% X to growing type type build ramping as driven revenue by to adoption Omnipod recurring

will U.S. and from a move expect starts MDI Libre We our Plus X to new customer as also technology. from GX, iOS benefits continue to anticipate We AID basis. grow customers year-over-year on

for XXXX revenue Our assumes and guidance XXXX. retention utilization U.S. in for relative similar trends pricing, to

we foreign currency are of a basis XXX International basis, points. reported approximately For to we an revenue assuming impact of XX% expect On growth XX%. Omnipod, unfavorable

in Germany U.K. those to as Omnipod continuing new customers and growth DASH from integrations from markets continued to the benefit and upgrade X. Omnipod expect We

ramp We year. growth continue Nordics we Italy Netherlands also expect the recent the the meaningfully to expect throughout to and contribute in ramp XXXX. our France the and And country more also to launches and in to

our be to Omnipod of we the will international trends adopt customers expect DASH international We XXXX, benefit X. pricing Omnipod new is growth. also upgrade in also our existing from Consistent revenue with Volume as revenue primary anticipate year-over-year. starts technology, expected to to from international customer we grow new driver customers saw

pricing XXXX. modest from trends Our international XXXX guidance and from to utilization and stable relative retention a benefit assumes

we XX% Delivery, Drug a to decline. for XX% Lastly, expect

margin. Turning gross to XXXX

communicated, As we which the improvement we channel. as shifted forward as compared to modest pricing to we of prior going years, previously expect pharmacy reflected benefit the

in becoming year, full approximately of of scale build the Malaysia manufacturing guidance the half our year. back efficiencies, gross slightly For margin continued facility reflects XX.X%. accretive including expect in we the and This the

gross ramp of by lower-margin benefits be to We international to partially expect offset business. margin the these our

impacted Additionally, not assumes tariffs. our our guidance that materially gross be will by business margin

pleased in by a manufacturing Malaysia. We very U.S. China and in have are position the complemented sites manufacturing here to robust

source us provides strategy challenging demonstrated which environment something Our optionality over developing monitoring. environment. includes and adaptability are materials, chain success This dual us chain and for great strategy with the is current supply has prior regionally supply this resiliency. located offers that we in Naturally, continuously

over points approximately basis XXXX. which expansion For XX.X%, the guiding of operating of we're XXX year, margin reflects

continue We will expand with pipeline expect on innovation. exciting our dollars fund further a R&D, which to basis continue margins of investing year-over-year more while to given to in we

in operating type continue we investments develop margin X type to particularly sales grow includes the Our as X and guidance base. customer market and marketing, also our

We business innovation have from margin growth over expansion continued many for coming long XXXX efficiently commercial term and opportunities robust investments and with the pipeline to further efforts. near and drive considerable the our in catalysts in scaling even

the Consistent and with to expect operating be margin the lower in we first in of improve gross half. margin second and year the half historical patterns,

For we rate to be XX%. to tax expect XXXX, effective our XX%

expect supply capital well expand with as we be our our higher operations to XXXX and as to and continue expansion. expenditures global We in support slightly as XXXX chain optimize manufacturing compared

expect continue organic cash cash the flow on growth strengthening annually free generating through to and our position positive and Additionally, balance we profitability. sheet

to our first XXXX Turning quarter guidance.

growth We XX% expect total of to XX%. company revenue

expect XX% For growth XX%. U.S. to we Omnipod, of

our Omnipod to the million in to dynamics. reminder, of million mid- prior first for is a stocking Adjusting $XX the unfavorable included first teens. U.S. this, growth high quarter $XX As of year quarter

points. exchange foreign decline impact X% Delivery Omnipod, we expect we XX%. of an a XX%. to approximately On of growth to International XX% Drug to we basis XXX expect unfavorable estimate And For revenue basis, reported

the by and significant immensely underpinned recent and ahead, our moat pleased In innovative feedback differentiation, unparalleled conclusion, product for we very our growth excited competitive are providers year and investments in and progress with patients. from technology, wide

to strong plans continue while flow are this do the growth with of diabetes to our delivery continued for for margin and key leading profile the all and Furthermore, better. changing catalysts. generating field our insulin the and free and will We profitability in expansion margin on positioned enable investments cash executing we people growth, of improving gross lives operating

our of To even summarize, value the long-term forward we to are topics these optimistic during future the creating. more I Day and are look in about we sharing June. Investor

Operator, questions. the we open that, line will for With

Operator

from Marcus JPMorgan. at our Instructions] first comes question Robbie [Operator And

Robert Marcus

Great. Congrats math a points X. quarter. type XX% in ask year-over-year, growth type about good to on U.S. I quarter-over-quarter growth My wanted rough XX% about in X the patients to

to in Just want what how 'XX. in point see and right if XXXX contributing is great trajectory the throughout to exit think that's ballparked about given the

James Hollingshead

Thanks, Robbie. your and question, Thanks for for congrats. thanks the

As had nice numbers on we've August, in not know, say ever and rates growth X out the breaking we will the ever categories. specific a label you had response NCS market. the the got we since from that since launch, we're I by really

label, we've part with starts with use in lot always X had X Omnipod important X of quarter. and of an a growing XX% got our new type and X how even off-label especially customer seen had a type both that's As Omnipod we've type of the X as And ramp. the business, nice you with We DASH. really to we type know, got before

growth on break to rates. we're but the splits the going out actual -- not So

Robert Marcus

how think just And comments on progress you will qualitatively. it and 'XX maybe

James Hollingshead

We're balance targeting it's really have and near-term in percentage 'XX even happy mix with overall, good We're X, the our that of grow continuing growth prescribers. to on X. new in prescribers we're early results for Obviously, really in grow Yes. type to seeing type seeing customer of We're to in the type X. it we're starts very response. bullish

we doctors And we clear saw for a so lift for said, type writing in as QX X.

us that. growth So getting in points. call of the into expansion just And finishing saw we're sales the more force,

call type points. So significantly X in we'd patients be those reaching more

us to beyond big us for that think and given, given market we're a label, driver a market So with which gives size years and course, the type X clear a advantage. growth first the in is the in we of of 'XX

Operator

Johnson We'll Jeff go at next Baird. to

Jeffrey Johnson

the well. on Congrats quarter as

ask maybe So a on Jim, to question. more wanted I of question another QX, qualitative

As past thought XX it of there's lot a on type to the months we've like over level, a the talked seems of at excitement. X leaders lot KOL especially to X,

the what TX? of an -- would kind of is, I why coming everybody I I love AID in an in about and at you're point. aren't think those leaders I population? who my the TXs or hear layer the prescriber PCPs. I'd not growing the type AID on in hear Maybe hearing space to sorry, the data docs we user on use thought excitement of my next get this to also have population the down IIT talk out Is system think how all just X of that TX to SECURE-TXD endos -- I'm like that on

James Hollingshead

on we're Yes, getting great in Omnipod Jeff. Thanks, X feedback type X.

First X, writing know, patients Omnipod call some as is endos endos Omnipod we thing to X. waiting patients Most X were for seeing the as investigators our in stay to got trial. and the participants at getting on label, close the point those our in indication. were were clinical the easy love but surprised of about our how talked market. some over And as in the already wanted in we off use XXXX, Omnipod we be that X And got for as saw you to that trial. to we I'll say label, proved Even Omnipod we're

So the as indication we for a saw we clear lift got use.

to because needs. adoption burden really that just as for already. who obviously, also patients But it's world, physicians we are frequent those MDI who it insulin, as of very them more, were on removes patients' basal-only using X injections the algorithm patient, go Omnipod patients to the it on adaptive see HCPs putting a their -- real know in so see already the we're physician the X. practices, real Omnipod is the it it bullish And hands, put seeing we're the on and on in a more And

process market. use not been pump education really So an do We patient the insulin has there have -- now go to type is develop population. X therapy in It until pump here. this therapy accepted to

And show it use. strong. really education, so and out reception But go early is how we have drive drive really, to to easy the awareness, is

note suggest ADA offered the just should their that in updated And type guidelines only should market therapy patients to the we're on insulin therapy. X course, AID the -- I'll with And be patients label. use the one intensive of

should reception. growth for So that drive us, and we're getting early great

Operator

move We'll to Bank Travis at next Steed America. of

Travis Steed

I on guidance. QX U.S. wanted to the ask

you think high it in I the teens kind mid- was excluding said of all to stocking, QX.

sure kind a thinking. of kind U.S. to or lower building that's conservatism QX up I just was Just want little the you're if of just guide than I how make for

Ana Chadwick

this Travis, is Ana. Great. Yes.

philosophy in correct. that high guiding do that normalized you're not and quarter quarter. absolutely that have full -- fourth is with U.S. we us consider the for XX% and the the in to in XX% bring event the XQ that of also has seasonality to But the we're The line guidance back year. that teens. importantly, first guidance for Our XXXX destocking mid- the the changed, between more to our to is And

Operator

to Michael Wolfe Polark next Research. go We'll at

Michael Polark

do the to guide, need you just incremental is what U.S. how expansion this can The growth get to to versus go question, you're what contribute that kind you through, the this the guidance from force sales today construction year? heads of in the these impactful of the meaning guide X/X way

James Hollingshead

-- the in well question, the has gone I guide our really expansion. hiring Mike. And the Thanks planned force includes for sales our really, rollout.

selling call a not for it's versus more force into separate reminder, TX. a the As model TX points. same It's

count, expanding just model. territories, well-established rep head we're expanding very So commercial

quarter fact we're encompasses that an the in so of reps that them the assumption are we're those those XX% pace, already -- and hired fashion. training at heads, a guide in through timely place the those And already we've filling

Operator

at We'll Atlantic. Issie go Kirby Redburn next to

Issie Kirby

wanted just ask type again. X I to about

standing Some terms perspective, of who color cohort is anything of touch we're patient upon getting some marketing leads from pump that therapy type X seeing physician Would perhaps there. is direct-to-consumer hear the you're adopters And there early to earlier? strategy adopting more a going. in in and what both love then these out and doing on your the just

James Hollingshead

Sure. across said Yes, a great What the we're Issie. kind reception there's label. existing call X to board. of were in different Obviously, before, is our of segments I'm type sure of really It's those I for of hear about from pattern seeing not you. clear waiting endocrinology, physician as practices emerging Thanks, points yet the strong patients. some

seeing down then as And type that lot there. really X of those really strong of And adoption we practices. X CGM, -- type also Omnipod so we're X in insulin a who into reach rapid-acting clear layer and reception writing we're PCPs seeing are

So I which a there's don't think yet about distinction patients are adopting.

experience, give point. patients. MDI on probably we it think the to able more type that I using But more be does as tilt we'll to insulin get intensive the X color

really the I on it's think DTC, powerful. Then

we've lends it's for so it's As times, train so promotion on. because adopt easy to couple X easy and to said and of direct-to-consumer and itself Omnipod before so a use well to so

for us. easier much it's So

would leads clear how label visualize X out patients advantage But easy use talk because X is for and our it the indication in Omnipod the it to and competitors Omnipod go about see for a have pump past, from X, only to for X who Omnipod them We had when use. type without lot X them of to the but over they were we having we offer a because them offer our Omnipod physician couldn't Omnipod route or generating X DASH. type actually for DTC, a patients we saw can

our way, X. and to is Omnipod an be about it think that already actually seeing They we're yield, what on type if want now a improved so can we X get to to They on, them And DTC. patients come happen help patient. you where see

that so to And think for be it's us way. promote that we've our we for in a saying able we out yields while of get to and better dividends been paying DTC, clearly

who patients off. practices force reaching through sales So arms be reaching X both that think, And we're strategy, and type calling I physician might are of that paying we're physician not we're promotional expansion, more the seeing a on. more

Operator

We'll take Morgan our next at question from Wood Stanley. Patrick

Patrick Wood

is keep very to adoption. you OUS unpack gave speeding Omnipod solution is chatted a AID And much sense there. training one. market the proper view really back it of of how there. for I'd in December. little with that But up a I'll the Omnipod X of Mass a Perfect. in of well X clearly, having the But midterm, And love sort side. sort Just some a relative function to drive we training? I'd sustainability to guys unpack of good love to helpful. details bit. to your like get to going really And

James Hollingshead

discrete, wearable, the Yes, wins waterproof, choice. Patrick. launched disposable, And of to the very so markets It's X -- provides that we of it's of X in -- of control. great Omnipod sensor all the say Omnipod Omnipod use, have the -- unobtrusive. this take it think It's it's easy X. most it. we benefits everywhere glycemic has And Thanks, to learn Europe, we've I frequently. and we in

we'll wide a that. choice continue sensor to for drive of range of there's So patients, and

first and be the we'll to then we the into GX. As prepared roll Netherlands GX continue to in quarter in remarks, U.K. and sensor our integration out bringing said here

of pump, the you're to on X. DASH. already on choice up wide conversions mostly, it's see And Omnipod contract if from very But We opens if think So into some patients. locked Omnipod DASH I a a on sensor for you're even do it market.

just and Omnipod And have seeing how pumps CGM not is is it wanted reaching portion previously see easy what a they And are when patients big can who Omnipod X market they're to so those pump X try as of have not a seen difficult. it, it tried. we're because they the already to that adopt opens would a up is on maybe use and MDI

we Both what we're France very market well. see U.K. go expectation. already take as great on really patients well. that's sustainable. And really our And roll well. winning we to continues X and and I product adoption those Netherlands, and is their all going And continue is think seeing. to past it launch markets, going still out, growing. anniversary, early our continue Omnipod is to early in every we'll Germany to are

Operator

comes question Our Blair. next Andrew Malgorzata Kaczor William with from

Macauley Kilbane

ask has Macauley like the This is a ] It the market mentioned. to as platform. already and on [ go Margaret started, you Wanted limited different tonight. Discovery on (sic) release Discover seems direction for

what forward So the has should thus far, how we feedback year. days, rollout wondering moving ultimately, the in been been throughout that integration the have what think early trends those about and utilization like

James Hollingshead

terrific response the both Omnipod Macauley. Yes. the about have who physician release. Discover. and limited patients it is days. We're But really using We're who just It using in from really early are from it. Thanks, practices excited market we are

users test So surveys measure -- and the on running It's and we lot a measure been of a -- because we all cloud-based and and on. and platform, so it's that. responses, we've

providers of so really Promoter very this And into high kind we're world in And to and Scores the more more Net from patients. get the and and both excited hands of practices patients. the and out the

Discover it is behind Omnipod it's a It's cloud-based through allows -- portal. a browser. accessible to point us The

computer you're on smartphone see any can it if through Patients practice. in a physician or workstation will typically in it smartphone. you their through your So access but your

the see if can It it you're you a they portal. long tricks. and gives you're browser, see and And patterns your usage It a As tells insulin. it access so and patient, you to about you and range you on. tips has allows of time how what as can using

their visibility improves So the gives therapy. usage more of own into experience, it really patients

for physicians, patients straightforward And are you in then, their your patients streamlines, physicians all for then cloud. it how see course, of And doing. facilitates to conversations. the reporting can see Really

It data. for physician get we together, sees data. about we're the And sees talk they really So So the in docs. us. market can when and think about for What for seeing? And visit, we it they excited physician what patient share and a is patient streamlines The experience retention care the will and drive drive -- going? improves workflows your say, patients, patient's it. therapy further are we really the it are how

Operator

go at Biegelsen next Fargo. Wells We'll Larry to

Larry Biegelsen

on X type in eye also type has comment X your halo take the effect your you creep seen XX% I XX% risk the having new can to almost a any to QX where grew do think type ball Is that starts -- that percent above a X seems sequentially on up type Is X? can -- -- type there XX% that quarter. new Over the like XX% heard type the now each in off you've U.S. you X And now. years XX% were it as focus launch DASH? X? you Is Jim, you of the for go X on the starts with

James Hollingshead

Thanks, Larry.

strategic us and Let for X. a to order. growth me X type focus huge those in both lead do continue reverse in to It's type

like the the And And on our so are a platform our beautiful of X force, product. teams, growing our about commercial it's both focused thing business. Omnipod a field is -- laser sides

product be be it's type huge year, are for and the or insulin X X that in patients, type well. is us the right? type continue leader a for X first So same the grow this and market grow in that the type users and who to So emphasis as X to market X type to

but the of of And the this all of users. over as know in is part we total very addressable terms in a still X. will type well, X type so are time, MDI X There's X, only And market mix, the obviously, to size continue runway in about In total you mix. I XX% X people type grow penetrated. in about X.Xx left the see much addressable market type type our think

there's market therapy. X And XX% Omnipod reduced so burden ready of their to that be for by

is really a market. X big The type

think we as beyond -- I part we'll XX% mix. grow a do of that our So

mix. But both X We the to and to X kind the X. continue on to Omnipod it sides grow haven't beyond expect we grow with we yet well do called the XX%, type type and expect of in ceiling business of

Operator

next Marie from BTIG. at comes Our Thibault question

Marie Thibault

guidance. in are bit this the bit looking to in and you R&D this on to like invest wanted gross lot all dynamics. it the ask But strong here looks really that margin a drivers got I margin you year. that of little Certainly QX, sustainable operating heard to here a a margin when I look at

XXX bit just expansion curious out higher. And so in this kind of why bps of of kind to XXXX. not But sneeze little Nothing I'm just a curious.

Ana Chadwick

up to to Yes. excited points. Great. Listen, Absolutely. we're XXX margin grow very basis

XX% gross which here. R&D. launches. over parts amount of invest we're and gross our revenue We're sales capitalizing margin, looking XX.X%, Some in to in come I've will the will probably going here as been mentioned from guided type margin the has international especially cycle. R&D. XX% be company of here a the of We're to to long-standing XX% marketing, before, to But in different as the in looking to absolutely goal in we be have and X at the

So be that that we invest. areas will

expenses guide gives the and that, the confidence In general Our us to will well flow process administrative to leverage, doing we will see here expand all to of as course, the cash profitability at of and continue of that and XX.X%. our free generate self-invest.

in move expansion margin we XXXX. we're forward as strong here So to looking

Operator

at Kratky to We'll Partners. go Leerink Mike next

Michael Kratky

dominant evolve other any as expectation get factors thinking One how in you in XXXX? have landscape your even competitors segment follow-up competitive there? approval? of X in And out the on is X. call competitive specifically, you advantage that How that about specific And could type market a type to are FDA the

James Hollingshead

for thanks Mike, question. the

first before, we As to market. said Omnipod X, obviously, we're

clinical need clearances. follow inherent advantages with we Omnipod competitors think own do and our to and data But just their overall. so X own demonstrate And has their

in the is Omnipod more QX. trend. of X true incumbent came all launched been through yet was MDI we've That consistent we off XXXX. combined. product as all overtook X than Omnipod X, in people a AID we of third It since very market and And competitors. of that all competitors brought to of our That's -- ever was true type So the

a already, obviously, of -- with that where That's winning been patients for comorbidities. tend lives of that market X live -- has the tend have they They conditions pump is type to X offer going on. their it's lot then that take type the the barrier patient so type a in typical pretty just to and with they have into And burden lead with. X complicated a adoption your lot

proved in use. the X participants to and investigators. It to SECURE-TXD Omnipod so simple surprised really the be both

of first So overtook as market, the the X existing go all into to our market type competitors. product we that with we're

market get indications. their think our to in and our we competitors if and to So have even are are we own position, a right very confident we in X win type clear the follow able

Operator

take for Raymond from We'll Jayson our next Bedford James question.

Jayson Bedford

progress the on here. Congrats

new just appreciate U.S. are in on customer Or the is one from also coming 'XX. all will So the maybe starts wondering, I quick guidance. you year-over-year? grow I'm that in comment the in just forecast, 'XX type type X that X? this year-over-year new embedded a But assuming the users the grow growth

James Hollingshead

grow X. market we're and type Thanks the X. type in Yes, type leader Jayson. to continue much for the us U.S. and first There's for question, the so it's NCS, X to market in lead imperative in overall and clear type We're in clear runway strategic in X a leader to and

imperative strategic us. that's a So for

we're guidance look have markets. what both splits not in those like, focused We broken but out growing on

Operator

to move Taylor we'll Matt at Next, Jefferies.

Matthew Taylor

on the one. of kind box this to wanted check Just

in pharmacy think competition the concerned I are about and some pricing. investors channel

you question so about see might give wanted in playing worried future. to that us moat. could aren't you risks And about kind if you how who see an there. for against your can Talk maybe the defend out investor be and of update those the for an why you, with And that I major how answer that

James Hollingshead

Yes. Thanks, Matt.

of in kind pharmacy are multiple -- We advantages there that. that sides to channel inherent have the

X the first pharmacy a experience took and then the few in it in pharmacy have The X.X ago, years to with first that of a now contract and We first were thing XXXX, years we the started enter get channel. We we 'XX years first lot to X, our coverage, think, our work doing And is Omnipod signed ago, channel then us with We and DASH X. I ramped Omnipod XXXX. teens. coverage.

So we're the pharmacy with XX% now lives covered benefit.

really has important. therapy reimbursement, which really, therapy is D We're AID -- on also the the only insulin market Part delivery only that

a the right the through organizational HCPCS right? a so of And of lot capabilities. opposed as advantage. benefit pharmacy clear top DME that's and the of so we built through reimbursed benefit, that, lot on And category. actually reimbursement a muscle then We get experience. have we We have So

your the Our product channel pick pharmacy in fits a box you go where your get pods because and insulin. you up

And kind so straightforward it's customers. very of for our pharmacy-style experience a

volume And have volume PBMs we through the the then on relationships significant and rebate, PBMs. money And do with pharmacy make channel. we and all

directions us. have and contracts we very for in have both beneficial also we So good relationships,

recognition fit coverage. an They number have very hit talking So doesn't very feel a we confident about do that stocking, in to a not to have very they co-pay moat. very all conscious it delivery, contracts. We're how to We well. position. it. the muscle. also economics. They in in clear a doesn't to get They do things. terms have can and build competitors patient have durable think does of have inherent of They those disadvantage experience. They It our of is channel we revenue It in pharmacy the pump the pharmacy the have pay-as-you-go terms fit that it and get

around trying competitors the And and follow for to of that very built competitors, but think mindful we've pharmacy we almost do that matter. conscious our we moats respectful channel. so distinct have we're we We're are everything very that

Operator

to We'll with O'Brien next Matthew Sandler. Piper move

Phillip Dantoin

the, Phil domestic wanted year, a bit call into more. to, year to which on full XX%, is for Omnipod guidance dig it, really I Matt. U.S. last year just maybe on QX. the little congrats And contribution in than from a place full I lower the high these to the This in Guiding for expectations, is as opportunity? nice iOS is a with being the honestly, Libre massive tailwinds, why to guess X it especially the number right mover first that type see relates X we'll quite teens -- set integration. type

Ana Chadwick

we're We do the like question. slowing down. not for feel Great. Thanks

in for step pharmacy year be little to We to in the In some anticipate on our as not I a a volume. we channel. for especially sure, We a come from second take comment XXX% will, bit want XXXX, U.S. the back accelerating, and dynamics. growth progresses. were the

So at as progress through year. the beginning we the of the year

headwind And price. quarters, -- normalizes earlier the that's some benefit at in not we is in the as growth. we go XXXX So as through year. That we that back a of variance had look from

pharmacy. of of our XXX% was volume much, As almost through quarter, pretty going third the

comparison. that's There's it So headwind, there's that one but do not a little of It's as price consideration. a a headwind. just bit as you

update are of to guidance. here guidance. high And extremely The our course, excited we end internally our by of end guidance. very the striving aiming our always as And team as XX%, the We by is completely the to and will high continue we're XX% year of for the progresses. excited for

James Hollingshead

Yes. And track goals. Phil, our I'll strong record just add, a have pretty of we achieving

we to line, strong XX% the to so we on continuing ambitions are And year our laser ninth were really focused for We like a the of have straight deliver grow growth to happy and top business. on plus continuing deliver growth.

Operator

take with our Nephron next from Pasquale We'll Chris Research. question

Christopher Pasquale

a guidance. I on bit push the margin wanted to little

if my back XX.X% 'XX right, onetime just below been is that XQ. would in So gross if charge have your margin not math slightly for

calling effectively flat OUS. is despite guidance be ramping, to for Malaysia improved in pricing So despite it it

it area? the the out offsets Or about milestone, flatten bit little meaningfully that get there? And gross then an term? Should a think importantly, you can longer we opportunity you to do more reached this higher? higher talk you maybe go margin you've can now it So XX% much how to in expect is

Ana Chadwick

job. We're gross the great. achievement team XX% a margin fourth has quarter fantastic the that proud at being very guiding Yes. and of No, XX.X%. done to of And

As mentioned now continue a to and industry-leading margin we're pricing has that here, tailwinds of our we gross push more growth level. benefited helped achieving before, we're And level from an at expansion. going moderate to I've

a You're want headwind Omnipod do I the us It gets GO absolutely charge. correct there. out point with close. to is that

as And -- And the that for at continues. full as guidance in XXXX, we our faster 'XX, materialized grew is in As U.S. mix. look international everybody a lower than as international than we we U.S. here knows, pricing year as our I

much that manufacturing of becoming here a margin, XXXX. second by of our accretive facility by we're we're Malaysia into gross growth looking in well continue to presents our than pace margin at going the improvements and offset So now to And that it's little the moderate our bit we're of a into industry-leading more terms I half but in to positioned more to indicate that really But drive levels. I the at headwind go back a be future.

Operator

take at Citi. our Joanne question Wuensch from We'll next

Joanne Wuensch

answered it that or been follows have so I'm far with fascinated investors. by our asked the conversations questions because

different over United it XX the frequently in to time X XX which past opportunity? that going the what revenue is, growth? if and I'm frame? important asked, more be XX-month so answer the which you we international months the next Or is would is And it for Is type adoption States? I'm And the pose go to here to

James Hollingshead

Joanne, platform, that X is international a with great laid type is have Both our X rollout type the the drive laid that's reason in U.S. extend And are lead to and available. question. right? we've -- that as X imperatives going the And big big. all of say platform, I'll are then the growth in markets growth them lead of lots those a -- what effect, -- we've out in strategic imperative, We're to

excited would really of about June Day. much being And Investor on so And at I growth in color we very in of opportunity. is -- we're our more growth provide tried so deliberately haven't not geography to a to terms because put we've premium on there's that what able all say

you'll and to hope X be I Day. Acton us able come Investor at on join for So June

Operator

Hollingshead. turn our conference to section. like I concludes would back Q&A the This to Jim

James Hollingshead

you ahead, these make you look progress global and want all against excited Insulet to again the joining just team dedication work. us to updating hard we of my to really about We're reiterate entire I as today. Insulet great and we for for your Thank the path forward objectives. strategic gratitude all for

to in patients patients reach everybody. I beyond. you, look forward and You and to XXXX, grow our and delivered a 'XX more in ton the to continuing Thank business

Operator

wonderful conference. Ladies your and a for participation, day. gentlemen, this you and Thank concludes today's have

all may disconnect. You

Insulet (PODD) 20 Feb 252024 Q4 Earnings call transcript